AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...
AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...
AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
Bleeding prophylaxis with the investigational factor VIIIa mimetic bispecific antibody Mim8 (denecimig) was superior to ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for ...
Furthermore, Viking is performing the Phase 3 VANQUISH-1 trial of VK2735 administered subcutaneously to patients for the ...
AbbVie seeks US FDA approval for Skyrizi subcutaneous induction for adults with moderately to severely active Crohn's disease: North Chicago, Illinois Wednesday, April 29, 2026, 1 ...
No. 11 / 2026Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight ...
Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: Operational and clinical drivers of subcutaneous PD-1/PD-L1 inhibitor ...
Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results